Dr. José Luís Domínguez-Escrig graduated in Medicine and Surgery in July1994, in Valencia, Spain, continuing his postgraduate training in the UK. Having completed his BST obtained the Membership of the Royal College of Surgeons of England in 2001 and the Fellowship of the Royal College of Surgeons in Urology, FRSC(Urol) in 2009.
From 2004 to 2006 he performed his research at the prestigious Northern Institute for Cancer Research-Newcastle University, UK. On completion of his research project, he submitted the Thesis “Tyrosine Kinase and Farnesyltarnsferase Inhibitors: Potential Selective Tailored Therapeutics in Bladder Cancer” and was awarded the Degree of Doctor of Medicine in 2006.
He has published in several international peer reviewed Journals and he has reviewed articles for Actas Urol Esp, BJU Int, Urol Oncology, Eur Urol Focus and the Journal of Urology and has imparted several lectures and presented at international meetings including AACR, AUA, EAU, BAUS, SIU and AEU.
He returned to Spain in 2011 and he is currently working as a Consultant Urology Surgeon at the Fundación Instituto Valenciano de Oncología (I.V.O.) in Valencia, where he combines his clinical work with an active involvement in translational research, participating as PI in several Clinical Trials in prostate and bladder cancer. Since 2015 is a systematic reviewer and Associated Member of the EAU NMIBC and UTUC Guidelines panel and also Spanish delegate to the European Board of Urology (E.B.U.), member of the F.E.B.U. examination committee. Since 2017 is member of the CUETO Group.
His main interests are urothelial carcinoma NMIBC and MIBC and the evaluation and development of focal therapies in Uro-oncology.